{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11","upperLimit":"35","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"Complete response (CR) is defined as complete disappearance of all measurable and non-measurable disease. No new lesions. No disease related symptoms. Partial response (PR) applies only to patients with least one measurable lesion. Greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received 1000 mg /m\\^2 of gemcitabine on Day 1 and 8 and 175 mg/m\\^2 of paclitaxel on Day 1 intravenously every 21 days for 6 cycles ( 1 cycle = 21 days)","id":"OG000","title":"Paclitaxel + Gemcitabine (Elderly Cohort: Age >= 70)"}],"paramType":"NUMBER","populationDescription":"Eligible patients aged 70 years and older who had received any treatment were included in the analysis. Patients aged 60 years or younger who served as a younger reference group for the pharmacokinetic study were excluded from analysis.","reportingStatus":"POSTED","timeFrame":"every week for the first 4 weeks and then every 3 weeks for up to 19 weeks","title":"Overall Confirmed Response Rate in the Patients Age 70 and Older (Complete and Partial Response)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}